Opinion|Videos|November 5, 2024
Integrating VMS Treatment Into Comprehensive Women’s Health Management
Key Takeaways
- Hormone therapy for VMS requires careful evaluation of risks, especially in women with pre-existing conditions.
- Non-hormonal treatments and lifestyle modifications are vital in managing menopause-related symptoms.
Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (FIFFICK) Considering the significant comorbidities often associated with menopause, such as cardiovascular disease and osteoporosis, how should VMS treatment be integrated into a broader health management plan for women?
Advertisement
Related to this article
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Survey findings show that although physicians view continuous glucose monitoring (CGM) as transformative, systemic barriers persist, leading to variable adoption across clinical practices.
Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville |
60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Contributor: Congress Can Bring Mental Health Care to the 21st Century
4
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
5